GCP-aligned quality and document control across multi-site, multi-sponsor clinical research operations.
ICH E6 (R3) shifted the ground under CROs: quality management is an explicit, risk-based system expectation — issues managed, root causes analyzed, CAPAs verified — not a binder of SOPs and a training log. Sponsor auditors and regulators alike now ask systems questions: how do you detect issues across studies, how do you escalate, how do you know your fixes worked?
Most CROs answer from a patchwork: CAPA in spreadsheets, SOPs on SharePoint, training in an LMS that does not know when an SOP changed. Every sponsor audit re-exposes the same seams.
E6 (R3) requires a quality management system proportionate to risk: processes defined, issues identified and escalated, root cause analysis where warranted, and corrective actions with effectiveness. Part 11 governs the electronic records; sponsor quality agreements add per-sponsor notification and oversight duties. ISO 9001 certification — increasingly a bid requirement — layers management review and internal audit on top.
Kintavo runs the QMS the framework describes: issue management with escalation rules, CAPA with verified effectiveness, SOPs linked to training, and sponsor-scoped reporting — one system across studies and sites.
A sponsor auditor opens with the systems question: how does the CRO detect recurring issues across studies? The quality director runs the trend view — protocol deviation categories across eleven active studies, one category flagged, an open CAPA linked. The auditor follows it: root cause, actions, and a 90-day effectiveness check with data. The finding count is zero; the bid team hears about it within the week.
"How do you know your fixes worked?" — the CAPA shows its effectiveness check: criteria, interval, data, signature. E6 (R3) questions are answered by records, not by narrative.
"It was a no-brainer for us to implement Kintavo."